drugset / Trial / NCT07422675
SAD Study in Patients With Parkinson's Disease and Motor Fluctuations
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a randomized, placebo-controlled, single ascending dose (SAD) study of SER-252 in participants with Parkinson's Disease (PD) and motor fluctuations.
Timeline
- Start
- 2026-02-01
- Primary completion
- 2027-01-31
- Completion
- 2027-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SER-252 | Unknown | 0.48 mg/kg | Subcutaneous |
| Subject | SER-252 | Unknown | 0.6 mg/kg | Subcutaneous |
| Subject | SER-252 | Unknown | 0.75 mg/kg | Subcutaneous |
| Subject | SER-252 | Unknown | 0.9 mg/kg | Subcutaneous |
| Subject | SER-252 | Unknown | 1 mg/kg | Subcutaneous |